UNSPSC 51294520: Paroxetine hydrochloride hemihydrate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent 2C19H20FNO3.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X2ELS050D8, chemically known as (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)-methyl)piperidine hydrochloride hemihydrate, but more generally known as paroxetine hydrochloride hemihydrate, which bears US NIH Compound Identifier 62878.

UNSPSC 51294520 Paroxetine hydrochloride hemihydrate (Commodity) shows minimal recent state and local procurement activity aligned directly with the code's scope. The three most recent opportunities on record are fundamentally mismatched to paroxetine or psychiatric pharmaceutical procurement: Seminole County, Florida's IFB60459723LAS solicits naloxone and drug deactivation systems (emergency response products, not maintenance therapeutics); Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription programs as a contracting model, not specific drug procurement; and Minnesota MMCAP's S1070000015802 addresses generic multi-source pharmaceuticals and OTC products through a cooperative purchasing alliance covering multiple states including Oregon. None of these opportunities explicitly seek paroxetine or antidepressant medications, and the code shows no dedicated state or local solicitations for this specific pharmaceutical active ingredient in the recent record.

The code records little actionable recent activity for business development professionals focused on paroxetine hydrochloride hemihydrate supply to state and local buyers. If pursuit is warranted, focus should be on cooperative purchasing vehicles (like MMCAP demonstrated in the Minnesota opportunity) that aggregate demand across multiple jurisdictions and channel supply through authorized wholesalers, and on state health and human services agencies that manage pharmacy benefit programs — the Texas HHS RFI indicates some states are evaluating direct manufacturer relationships that could create new pathways for branded or specialized formulations. However, the absence of direct paroxetine solicitations suggests demand at the state and local level is satisfied through existing wholesaler relationships and group purchasing organization contracts rather than through discrete competitive bidding processes. Monitor health and human services RFPs and cooperative purchasing alliance renewals in states with substantial Medicaid or employee health programs as the likeliest near-term opportunity sources.